As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...
LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...
Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns.
X Genomics Inc . (NASDAQ:TXG) reported its Q4 2024 earnings, revealing a larger-than-expected loss per share and a decline in revenue compared to the previous year. The company posted an EPS of -$0.40 ...
2d
Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales ...
Request To Download Free Sample of This Strategic Report @ Highlighted with 42 tables and 37 figures, this 121-page report Europe Transcriptomics Market 2021-2031 by Component (Instruments, ...
North America transcriptomics market is projected to grow by 10.3% annually in the forecast period and reach $6,124.0 million by 2031, driven by the surging demand for personalize ...
Landmark single-cell dataset of one billion cells will be used to train new AI models to advance understanding of cellular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback